NAUT vs. SENS, ALNT, EYPT, AEHR, QSI, QTRX, FEIM, MASS, SEER, and KEQU
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Senseonics (SENS), Allient (ALNT), EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Frequency Electronics (FEIM), 908 Devices (MASS), Seer (SEER), and Kewaunee Scientific (KEQU). These companies are all part of the "measuring and control equipment" industry.
Nautilus Biotechnology vs.
Senseonics (NYSE:SENS) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations.
Senseonics currently has a consensus target price of $2.00, suggesting a potential upside of 233.39%. Nautilus Biotechnology has a consensus target price of $2.42, suggesting a potential upside of 218.82%. Given Senseonics' stronger consensus rating and higher probable upside, research analysts plainly believe Senseonics is more favorable than Nautilus Biotechnology.
Senseonics has higher revenue and earnings than Nautilus Biotechnology. Senseonics is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Nautilus Biotechnology has a net margin of 0.00% compared to Senseonics' net margin of -362.30%. Nautilus Biotechnology's return on equity of -28.85% beat Senseonics' return on equity.
12.4% of Senseonics shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 3.6% of Senseonics shares are owned by insiders. Comparatively, 40.5% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Senseonics and Senseonics both had 2 articles in the media. Senseonics' average media sentiment score of 0.86 beat Nautilus Biotechnology's score of -0.50 indicating that Senseonics is being referred to more favorably in the media.
Senseonics received 2 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. However, 18.18% of users gave Nautilus Biotechnology an outperform vote while only 15.38% of users gave Senseonics an outperform vote.
Senseonics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
Summary
Senseonics and Nautilus Biotechnology tied by winning 8 of the 16 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nautilus Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:NAUT) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy NAUT Stock Free NAUT Stock Alerts